A paraplegic patient will receive gene therapy for the first time as a result of a partnership between Stand Up Therapeutics and VectorBuilder


A paraplegic patient will receive gene therapy for the first time as a result of a partnership between Stand Up Therapeutics and VectorBuilder 1
Spread the love

For people with paralysing spinal cord injuries, Stand Up Therapeutics Co., Ltd. of South Korea specialises in investigating gene treatments. Leaders in the field of gene delivery technology Stand Up Therapeutics and VectorBuilder Inc. will create a GMP-grade gene delivery system as a result of their cooperation.

The largest manufacturer of unique viral and non-viral gene delivery vectors in the world is called VectorBuilder. It is based in Chicago, Illinois, and has offices throughout the world, including North America, Europe, China, Japan, Korea, Australia, and Israel. Every year, experts from all over the world create more than 80,000 unique vectors for use in their research. More than 50,000 customers, including the top pharmaceutical businesses and institutes in the globe, rely on VectorBuilder’s Good Manufacturing Practice (GMP) facilities for its gene delivery systems. We offer gene treatment choices as well as delivery strategies.

According to the terms of their contract, VectorBuilder will produce and market gene therapy goods created by Stand Up Therapeutics in the future. The goal is to become the best in the world.

Bruce Lahn, a chief scientist at VectorBuilder, said that his company is “very intrigued” in Stand Up Therapeutics’ gene therapy for the treatment of all forms of paralysis. I think this is a fantastic chance for VectorBuilder to sell this product to Stand Up for Patients around the world because they are without a doubt the industry leaders in the design and GMP production of gene delivery vectors.

According to Dr. Junsang Yoo, the business’s CEO, “Stand Up Therapeutics is the only company in the world with the technology to treat paralysed people as a result of spinal cord damage” (STUP-001). The Stand Up Therapeutics team is committed to creating a cure for those who have suffered devastating paralysis. Stand Up Therapeutics intends to create medicines for Parkinson’s disease (STUP-002), stroke (STUP-003), spinal stenosis (STUP-004), and myocardial infarction using the direct cross-differentiation PIPELINE technology (STUP-005).

See also  Developer Bruce Strebinger's biggest highlights of multiplex living

The STUP-001 gene therapy treatment for SCI is expected to start phase I/IIa clinical research with four paraplegic patients in the first quarter of 2023.

Gz4A uoQmqv 0ZCh0v3ph77RzUp4OCF 7ZcuKt2QMV6sONeHVtxF5IgDujv9MROvSa9kuppt6KwG9vni braE507U2eTt0JlZEAhoc3bhzC6IhGMIJcwBWqX0x1nRU50UwDdhtgPSuD6w 2G1blZXNwufjZwFDhy Ww

Speaking of Stand Up Therapeutics Co., Ltd 

Regenerative neurology, specifically fibroblast-to-motor-neuron in vivo gene therapy, is the company’s main focus. These treatments were created using modern medical techniques and technology. Patients with varied degrees of paralysis will benefit from Stand Up Therapeutics’ direct lineage reprogramming approach. It is envisaged that direct lineage reprogramming will be employed to treat patients with spinal cord and brain injuries. This group makes up about 1.9 per cent of the world’s population. Stand Up Therapeutics will be able to produce more medications if it can increase the dependability and security of direct reprogramming and gene therapy.

See http://stutps.com for more information.


Spread the love

Abhay Singh

Abhay Singh is a seasoned digital marketing expert with over 7 years of experience in crafting effective marketing strategies and executing successful campaigns. He excels in SEO, social media, and PPC advertising.